IS6892A - Lyfjasamsetningar, skammtaform og aðferðir til aðgefa epóþílon um munn - Google Patents
Lyfjasamsetningar, skammtaform og aðferðir til aðgefa epóþílon um munnInfo
- Publication number
- IS6892A IS6892A IS6892A IS6892A IS6892A IS 6892 A IS6892 A IS 6892A IS 6892 A IS6892 A IS 6892A IS 6892 A IS6892 A IS 6892A IS 6892 A IS6892 A IS 6892A
- Authority
- IS
- Iceland
- Prior art keywords
- epothilone
- methods
- dosage forms
- pharmaceutical formulations
- administering oral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26422801P | 2001-01-25 | 2001-01-25 | |
US29001901P | 2001-05-11 | 2001-05-11 | |
PCT/US2002/002518 WO2002058701A1 (en) | 2001-01-25 | 2002-01-25 | Pharmaceutical dosage forms of epothilones for oral administration |
Publications (1)
Publication Number | Publication Date |
---|---|
IS6892A true IS6892A (is) | 2003-07-24 |
Family
ID=26950349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS6892A IS6892A (is) | 2001-01-25 | 2003-07-24 | Lyfjasamsetningar, skammtaform og aðferðir til aðgefa epóþílon um munn |
Country Status (26)
Country | Link |
---|---|
US (2) | US6576651B2 (is) |
EP (1) | EP1361877A1 (is) |
JP (1) | JP2004528287A (is) |
KR (1) | KR20040025888A (is) |
CN (1) | CN1268336C (is) |
AR (1) | AR035078A1 (is) |
BG (1) | BG108027A (is) |
BR (1) | BR0206695A (is) |
CA (1) | CA2434584A1 (is) |
CZ (1) | CZ20032023A3 (is) |
EE (1) | EE200300329A (is) |
HR (1) | HRP20030674A2 (is) |
HU (1) | HUP0303800A3 (is) |
IL (1) | IL156759A0 (is) |
IS (1) | IS6892A (is) |
MX (1) | MXPA03006476A (is) |
NO (1) | NO20033343L (is) |
NZ (1) | NZ526871A (is) |
PE (1) | PE20020853A1 (is) |
PL (1) | PL368636A1 (is) |
RU (1) | RU2291695C2 (is) |
SK (1) | SK9212003A3 (is) |
TW (1) | TWI250017B (is) |
UY (1) | UY27138A1 (is) |
WO (2) | WO2002058699A1 (is) |
YU (1) | YU58103A (is) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204388B1 (en) * | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
EP0977563B1 (en) | 1996-12-03 | 2005-10-12 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US20050043376A1 (en) * | 1996-12-03 | 2005-02-24 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
US6780620B1 (en) * | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
JP2003502449A (ja) | 1999-06-10 | 2003-01-21 | ハネウエル・インターナシヨナル・インコーポレーテツド | フォトリソグラフィ用スピンオンガラス反射防止コーティング |
US6824879B2 (en) | 1999-06-10 | 2004-11-30 | Honeywell International Inc. | Spin-on-glass anti-reflective coatings for photolithography |
US8618085B2 (en) * | 2000-04-28 | 2013-12-31 | Koasn Biosciences Incorporated | Therapeutic formulations of desoxyepothilones |
PL367260A1 (en) * | 2001-01-25 | 2005-02-21 | Bristol-Myers Squibb Company | Parenteral formulation containing epothilone analogs |
WO2002058699A1 (en) | 2001-01-25 | 2002-08-01 | Bristol-Myers Squibb Company | Pharmaceutical forms of epothilones for oral administration |
RU2003128311A (ru) | 2001-02-20 | 2005-03-10 | Бристол-Маерс Сквибб Компани (Us) | Способ лечения резистентных опухолей с применением аналогов эпотилона |
CA2440555A1 (en) * | 2001-03-14 | 2002-09-19 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
EP1472574A4 (en) | 2001-11-15 | 2005-06-08 | Honeywell Int Inc | ANTI-REFLECTIVE COATINGS DESIGNED TO BE INSTALLED BY ROTATION FOR PHOTOLITHOGRAPHY |
AU2003218107A1 (en) * | 2002-03-12 | 2003-09-29 | Bristol-Myers Squibb Company | C12-cyano epothilone derivatives |
TW200403994A (en) * | 2002-04-04 | 2004-03-16 | Bristol Myers Squibb Co | Oral administration of EPOTHILONES |
TW200400191A (en) * | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
DK1506203T3 (da) | 2002-08-23 | 2007-05-14 | Sloan Kettering Inst Cancer | Syntese af epothiloner, mellemprodukter deraf, analoger deraf og anvendelser deraf |
EP1551425A4 (en) * | 2002-10-09 | 2006-09-20 | Kosan Biosciences Inc | THERAPEUTIC FORMULATIONS |
US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
DK2792363T3 (da) * | 2003-08-26 | 2016-09-26 | Shire Biopharmaceuticals Holdings Ireland Ltd | Farmaceutisk formulering, der omfatter lanthanforbindelser |
US20050171167A1 (en) * | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
DK1687066T3 (da) | 2003-11-14 | 2012-11-26 | Brigham & Womens Hospital | Fremgangsmåder til immunmodulering |
US8053159B2 (en) | 2003-11-18 | 2011-11-08 | Honeywell International Inc. | Antireflective coatings for via fill and photolithography applications and methods of preparation thereof |
US20090004277A1 (en) * | 2004-05-18 | 2009-01-01 | Franchini Miriam K | Nanoparticle dispersion containing lactam compound |
US7244765B2 (en) * | 2004-06-25 | 2007-07-17 | Cytokine Pharmasciences, Inc | Guanylhydrazone salts, compositions, processes of making and methods of using |
US20060069136A1 (en) * | 2004-09-24 | 2006-03-30 | Ulrich Klar | Use of Epothilones in the treatment of bone metastasis |
US20060134214A1 (en) * | 2004-11-18 | 2006-06-22 | Ismat Ullah | Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof |
MX2007005763A (es) * | 2004-11-18 | 2007-07-20 | Squibb Bristol Myers Co | Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma. |
AR057325A1 (es) * | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
US8642246B2 (en) | 2007-02-26 | 2014-02-04 | Honeywell International Inc. | Compositions, coatings and films for tri-layer patterning applications and methods of preparation thereof |
SI2276485T1 (sl) | 2008-04-24 | 2014-10-30 | Bristol-Myers Squibb Company | Uporaba epotilona D pri zdravljenju Tau- povezanih bolezni, vključno z Alzheimerjevo boleznijo |
US8557877B2 (en) | 2009-06-10 | 2013-10-15 | Honeywell International Inc. | Anti-reflective coatings for optically transparent substrates |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
US8864898B2 (en) | 2011-05-31 | 2014-10-21 | Honeywell International Inc. | Coating formulations for optical elements |
CN102276433B (zh) * | 2011-06-30 | 2016-04-20 | 南昌大学 | 木豆素c及其衍生物及其在制备抗癌药物中的应用 |
EP3194502A4 (en) | 2015-04-13 | 2018-05-16 | Honeywell International Inc. | Polysiloxane formulations and coatings for optoelectronic applications |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4138042C2 (de) | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel |
DE19542986A1 (de) | 1995-11-17 | 1997-05-22 | Biotechnolog Forschung Gmbh | Epothilon-Derivate und deren Verwendung |
DK0903348T4 (da) | 1995-11-17 | 2008-10-20 | Biotechnolog Forschung Gmbh | Epothilonderivater og fremstilling deraf |
DE19639456A1 (de) | 1996-09-25 | 1998-03-26 | Biotechnolog Forschung Gmbh | Epothilon-Derivate, Herstellung und Mittel |
US6441025B2 (en) * | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
ES2448467T3 (es) * | 1996-03-12 | 2014-03-14 | Pg-Txl Company, L.P. | Profármacos solubles en agua |
DE19645362A1 (de) | 1996-10-28 | 1998-04-30 | Ciba Geigy Ag | Verfahren zur Herstellung von Epothilon A und B und Derivaten |
DE19636343C1 (de) * | 1996-08-30 | 1997-10-23 | Schering Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B |
NZ334821A (en) | 1996-08-30 | 2000-12-22 | Novartis Ag | Method for producing epothilones |
DE19645361A1 (de) | 1996-08-30 | 1998-04-30 | Ciba Geigy Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II |
DE59711647D1 (de) | 1996-11-18 | 2004-06-24 | Biotechnolog Forschung Gmbh | Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel |
US6515016B2 (en) | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
EP0977563B1 (en) * | 1996-12-03 | 2005-10-12 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
DE19701758A1 (de) | 1997-01-20 | 1998-07-23 | Wessjohann Ludgar A Dr | Epothilone-Synthesebausteine |
PT975638E (pt) | 1997-02-25 | 2002-12-31 | Biotechnolog Forschung Mbh Gbf | Epothilons modificados nas cadeias laterais |
DE19713970B4 (de) | 1997-04-04 | 2006-08-31 | R&D-Biopharmaceuticals Gmbh | Epothilone-Synthesebausteine II - Prenylderivate |
US6348551B1 (en) | 1997-04-18 | 2002-02-19 | Studiengesellschaft Kohle Mbh | Selective olefin metathesis of bifunctional or polyfunctional substrates in compressed carbon dioxide as reaction medium |
DE19720312A1 (de) | 1997-05-15 | 1998-11-19 | Hoechst Ag | Zubereitung mit erhöhter in vivo Verträglichkeit |
DE19821954A1 (de) | 1997-05-15 | 1998-11-19 | Biotechnolog Forschung Gmbh | Verfahren zur Herstellung eines Epothilon-Derivats |
DE19726627A1 (de) | 1997-06-17 | 1998-12-24 | Schering Ag | Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
US6384230B1 (en) | 1997-07-16 | 2002-05-07 | Schering Aktiengesellschaft | Thiazole derivatives, method for their production and use |
PT1005465E (pt) | 1997-08-09 | 2007-10-18 | Bayer Schering Pharma Ag | Novos derivados da epotilona, processo para a sua preparação e sua utilização farmacêutica |
US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
KR20060002022A (ko) | 1998-02-05 | 2006-01-06 | 노파르티스 아게 | 유기화합물 함유 조성물 |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
AU758526B2 (en) | 1998-02-25 | 2003-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues therof |
US6380395B1 (en) | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
WO2000000485A1 (de) | 1998-06-30 | 2000-01-06 | Schering Aktiengesellschaft | Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung |
IL143069A0 (en) | 1998-11-20 | 2002-04-21 | Kosan Biosciences Inc | Recombinant methods and materials for producing epothilone and epothilone derivatives |
WO2000037473A1 (en) | 1998-12-22 | 2000-06-29 | Novartis Ag | Epothilone derivatives and their use as antitumor agents |
JP2002537301A (ja) | 1999-02-18 | 2002-11-05 | シエーリング アクチエンゲゼルシャフト | 16−ハロゲン−エポチロン誘導体類、それらの生成方法、及びそれらの医薬的使用 |
US6211412B1 (en) | 1999-03-29 | 2001-04-03 | The University Of Kansas | Synthesis of epothilones |
AR023792A1 (es) | 1999-04-30 | 2002-09-04 | Bayer Schering Pharma Ag | Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos |
WO2002058699A1 (en) | 2001-01-25 | 2002-08-01 | Bristol-Myers Squibb Company | Pharmaceutical forms of epothilones for oral administration |
WO2002058700A1 (en) | 2001-01-25 | 2002-08-01 | Bristol-Myers Squibb Company | Methods of administering epothilone analogs for the treatment of cancer |
CA2440555A1 (en) | 2001-03-14 | 2002-09-19 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
-
2002
- 2002-01-22 WO PCT/US2002/001693 patent/WO2002058699A1/en not_active Application Discontinuation
- 2002-01-22 NZ NZ526871A patent/NZ526871A/en unknown
- 2002-01-25 IL IL15675902A patent/IL156759A0/xx unknown
- 2002-01-25 AR ARP020100288A patent/AR035078A1/es unknown
- 2002-01-25 UY UY27138A patent/UY27138A1/es not_active Application Discontinuation
- 2002-01-25 PL PL02368636A patent/PL368636A1/xx not_active Application Discontinuation
- 2002-01-25 CA CA002434584A patent/CA2434584A1/en not_active Abandoned
- 2002-01-25 MX MXPA03006476A patent/MXPA03006476A/es unknown
- 2002-01-25 TW TW091101287A patent/TWI250017B/zh not_active IP Right Cessation
- 2002-01-25 CN CNB028069927A patent/CN1268336C/zh not_active Expired - Fee Related
- 2002-01-25 HU HU0303800A patent/HUP0303800A3/hu unknown
- 2002-01-25 EE EEP200300329A patent/EE200300329A/xx unknown
- 2002-01-25 PE PE2002000061A patent/PE20020853A1/es not_active Application Discontinuation
- 2002-01-25 WO PCT/US2002/002518 patent/WO2002058701A1/en not_active Application Discontinuation
- 2002-01-25 KR KR10-2003-7009781A patent/KR20040025888A/ko not_active Application Discontinuation
- 2002-01-25 CZ CZ20032023A patent/CZ20032023A3/cs unknown
- 2002-01-25 BR BR0206695-5A patent/BR0206695A/pt not_active IP Right Cessation
- 2002-01-25 US US10/057,390 patent/US6576651B2/en not_active Ceased
- 2002-01-25 JP JP2002559035A patent/JP2004528287A/ja not_active Withdrawn
- 2002-01-25 EP EP02723073A patent/EP1361877A1/en not_active Withdrawn
- 2002-01-25 YU YU58103A patent/YU58103A/sh unknown
- 2002-01-25 RU RU2003126174/15A patent/RU2291695C2/ru not_active IP Right Cessation
- 2002-01-25 SK SK921-2003A patent/SK9212003A3/sk unknown
-
2003
- 2003-07-24 BG BG108027A patent/BG108027A/bg unknown
- 2003-07-24 NO NO20033343A patent/NO20033343L/no not_active Application Discontinuation
- 2003-07-24 IS IS6892A patent/IS6892A/is unknown
- 2003-08-25 HR HR20030674A patent/HRP20030674A2/hr not_active Application Discontinuation
-
2005
- 2005-06-09 US US11/149,501 patent/USRE40387E1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
IL156759A0 (en) | 2004-02-08 |
HUP0303800A3 (en) | 2005-02-28 |
PE20020853A1 (es) | 2002-09-27 |
USRE40387E1 (en) | 2008-06-17 |
RU2291695C2 (ru) | 2007-01-20 |
EE200300329A (et) | 2003-10-15 |
EP1361877A1 (en) | 2003-11-19 |
WO2002058701A1 (en) | 2002-08-01 |
CZ20032023A3 (cs) | 2005-03-16 |
UY27138A1 (es) | 2002-08-30 |
KR20040025888A (ko) | 2004-03-26 |
NO20033343D0 (no) | 2003-07-24 |
BR0206695A (pt) | 2004-04-20 |
JP2004528287A (ja) | 2004-09-16 |
US20020177615A1 (en) | 2002-11-28 |
RU2003126174A (ru) | 2005-02-27 |
WO2002058699A1 (en) | 2002-08-01 |
MXPA03006476A (es) | 2003-09-22 |
HUP0303800A2 (hu) | 2004-03-29 |
NO20033343L (no) | 2003-09-24 |
SK9212003A3 (en) | 2004-11-03 |
YU58103A (sh) | 2006-03-03 |
PL368636A1 (en) | 2005-04-04 |
AR035078A1 (es) | 2004-04-14 |
TWI250017B (en) | 2006-03-01 |
CN1268336C (zh) | 2006-08-09 |
BG108027A (bg) | 2004-12-30 |
AU2002253880B2 (en) | 2006-11-09 |
CN1498106A (zh) | 2004-05-19 |
CA2434584A1 (en) | 2002-08-01 |
NZ526871A (en) | 2006-01-27 |
US6576651B2 (en) | 2003-06-10 |
HRP20030674A2 (en) | 2005-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS6892A (is) | Lyfjasamsetningar, skammtaform og aðferðir til aðgefa epóþílon um munn | |
DK1478339T3 (da) | Farmaceutiske formuleringer af antineoplastiske midler, specielt temozolomid, fremgangsmåder til fremstilling og anvendelse heraf | |
PL356358A1 (en) | Solid dosage form of someticone for oral administration | |
AU2002357012A1 (en) | Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof | |
NO20042993L (no) | Formulering og doseringsform for kontrollert levering av terapeutiske midler | |
NO20062504L (no) | Sammensetninger og doseringsformer for forbedret absorpsjon | |
IS7691A (is) | Lyfjasamsetningar til að meðhöndla æxli | |
ATE282428T1 (de) | Pharmazeutische dosierungsform von amorphem nilfenavir mesylat | |
IL166489A (en) | Oral dosage form in single-dose administration containing at least two layers for the administration and use of flipridone | |
EE200300207A (et) | Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon | |
NO20043904L (no) | Oral doseringsform inneholdende en PDE4-hemmer som aktivt ingrediens og polyvinylpyrrolidon som eksipiens | |
NO20035438L (no) | Farmasoytisk formulering for effektiv administrering av apomorfin, 6aR-(-)-N-propyl-norapomorfin og deres derivater og prodrugs derav | |
NO20041607L (no) | Doseringsregime og farmasoytisk preparat for nodprevensjon | |
IS7481A (is) | Epóthílon til gjafar um munn | |
ZA200303037B (en) | Herbal pharmaceutical composition for treatment of HIV/Aids patients. | |
SG116507A1 (en) | Pharmaceutical dosage form and method of making. | |
DK1334717T3 (da) | Farmaceutiske sammensætninger til oral og topisk administrering | |
DK1417189T3 (da) | Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf | |
NO20043333L (no) | Farmasoytiske parvastatinformuleringer og fremgangsmater for anvendelse av dem | |
EE200300501A (et) | Ninna manustatavad imidasotriasinooni sisaldavad kompositsioonid | |
FI20000780A (fi) | Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi | |
IS6532A (is) | Lyfjaform til stýrðrar losunar á síprófloxasíni með inntöku um munn einu sinni á dag | |
IS2331B (is) | 2-arýlimínó-2,3-díhýdróþíasólafleiður, aðferðir til að framleiða þær og meðferðarfræðileg notkun þeirra | |
HK1065305A1 (en) | Substituted 4-aminocyclohexanol derivatives | |
NO20034985L (no) | Nye 5-tio-SS-D-xylopyranosid-derivater, fremgangsmåte for fremstilling derav, farmasöytiske blandinger inneholdende dem og den terapeutiskeanvendelse derav |